evipedia.ai
← Back

Cortagen for Health & Longevity

Evidence Review created on 08/31/2026 using AI4L / Opus 5

Also known as: AEDP, Ala-Glu-Asp-Pro, Alanyl-Glutamyl-Aspartyl-Proline, Cortagen Bioregulator, Kortagen

Motivation

Cortagen is a laboratory-made peptide of four amino acids: alanine, glutamic acid, aspartic acid and proline. It was designed in Russia to reproduce, in one defined molecule, the active fraction of an older brain-tissue extract long used there in neurology. Interest in it comes from an unusual proposal: that a molecule this small enters the cell nucleus and changes which genes a cell reads, instead of acting on a receptor at the cell surface as most drugs do.

It belongs to a family of very short peptides developed from the 1970s onward at a St. Petersburg research institute, each one matched to a particular organ; Cortagen is the brain-cortex member. Most of what has been published on it concerns nerve repair and the brain’s response to poor blood supply in animals, and nearly all of it comes from the same circle of laboratories.

This review examines what Cortagen is, how it is proposed to work, what the published record does and does not show, how it has been used, and where the evidence stops.

Benefits - Risks - Protocol - Conclusion

Sources that treat Cortagen itself, or the short-peptide bioregulator class it belongs to, in enough depth to be worth reading in full.

Two of the three items below, and the large majority of all Cortagen literature, originate from the St. Petersburg Institute of Bioregulation and Gerontology and its collaborators; that institute, its founder and their commercial partners hold patents on these peptides and derive revenue from their sale, a direct financial interest that runs through almost the entire evidence base for this compound.

Fewer than five items are listed, and none comes from a priority platform. On-site and web searches of Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension and Lifespan.io returned nothing on Cortagen; the closest match is a short segment of one Huberman Lab peptide episode on the sibling peptide Epitalon, too brief and too far from this compound to qualify. Beyond the three papers above, the only material that names Cortagen at length is vendor marketing, so the list has deliberately not been padded.

Grokipedia

Pinealon and Cortagen

Covers Cortagen jointly with the sibling peptide Pinealon, summarising the Khavinson programme’s development history, claimed cellular mechanisms, research findings and regulatory standing in one place.

Examine

No Examine article exists for Cortagen.

Examine.com covers dietary supplements and food-derived compounds; Cortagen is sold outside Russia only as a research chemical, which falls outside that scope.

ConsumerLab

No ConsumerLab article exists for Cortagen.

ConsumerLab tests retail supplements sold in the United States; no Cortagen product is sold through that channel, so none has been submitted for testing.

Systematic Reviews

Systematic reviews and meta-analyses that bear on Cortagen or on the peptide class it belongs to.

Cortagen’s central trade-off is claimed nerve and brain recovery set against entirely uncharacterised harm. The benefit side is represented only indirectly, through the two class-level reviews above; no systematic review or meta-analysis anywhere addresses Cortagen’s own safety, so the risk side of the trade-off is unrepresented in this literature.

Mechanism of Action

Cortagen is the tetrapeptide alanine-glutamic acid-aspartic acid-proline (Ala-Glu-Asp-Pro, abbreviated AEDP), produced by synthesising the amino-acid signature of Cortexin, a polypeptide extract of cattle brain cortex (Anisimov et al., 2004). The proposed mechanism is not receptor signalling. Peptides this small are held to cross the cell and nuclear membranes, bind double-stranded DNA at gene promoter regions and bind histones, the spool proteins that DNA is wound around, thereby changing which genes a cell can transcribe (Khavinson et al., 2021, from the institute that patents and sells these peptides). Entry into cells is attributed to proton-coupled oligopeptide transporters (membrane pumps that normally carry two- and three-amino-acid fragments of digested protein) (Khavinson et al., 2022). The competing reading is that an uncharged four-residue peptide cannot survive plasma peptidases (enzymes that cut peptides apart) long enough to reach any nucleus, and that reported effects reflect amino-acid supply or non-specific stress responses rather than sequence-specific gene targeting.

Pharmacologically the compound is barely characterised. No human pharmacokinetic study, meaning a study of how the body absorbs and clears a substance, has been published; peptides of this length are hydrolysed by plasma and tissue peptidases within minutes, so exposure is brief and any lasting effect must outlive the molecule. It is not handled by the cytochrome P450 enzymes (the liver enzyme family that clears most drugs), so classical metabolic interactions are not expected. Selectivity is asserted to be sequence-specific rather than receptor-mediated, and tissue distribution has never been mapped with a labelled compound in humans.

Historical Context & Evolution

Cortagen’s ancestor is Cortexin, a polypeptide extract of cattle brain cortex introduced in Soviet neurology for head injury, stroke recovery and childhood neurological disorders. The original intended use was therefore clinical neurology, not longevity. Work at the St. Petersburg Institute of Bioregulation and Gerontology, which patents and sells these peptides, fractionated such organ extracts, identified di- and tetrapeptides as the active components, and synthesised defined replacements. Cortagen was the brain-cortex product of that programme (Anisimov et al., 2004).

The move toward health optimisation came from the finding, again from that institute, that these peptides act tissue-specifically in organ culture: each stimulated growth of tissue samples from the organ its parent extract came from (Khavinson, 2001). If a four-amino-acid molecule could restore a tissue’s own gene programme, the reasoning ran, it might reverse age-related decline in that tissue rather than merely treat injury.

That reasoning is contested, so what the findings actually were matters more than their reception. The rodent nerve-regeneration results are quantitatively specific and have not been contradicted by any published replication attempt; equally, no independent group has reproduced them. The chromatin work, on how DNA is packaged inside the nucleus, has since been partially reproduced outside Russia (Lezhava et al., 2023), while parallel studies from within the programme found Cortagen inert where sibling peptides were active (Kuznik et al., 2008). What has changed is not that the early work was overturned, but that the effects proved narrower and less consistent than the founding hypothesis predicted.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the human material consists of uncontrolled clinical reports from the originating programme, not a clinical endpoint or a validated clinical surrogate replicated across two or more trials.

Medium 🟩 🟩

No benefit reaches Medium either: there is no single controlled human trial and no consistent observational dataset for Cortagen; what remains is rodent experimentation and cell-culture assay work.

Low 🟩

Recovery of Function After Peripheral Nerve Injury

Cortagen’s founding claim: faster functional recovery after a severed peripheral nerve, attributed to peptide-driven gene activation in nerve tissue. The evidence base is two rat studies plus an undocumented human assertion of post-traumatic nerve recovery, reported without design, comparator or sample size. Rodent signal specific; human signal unaudited.

Magnitude: In rats given 10 µg/kg intramuscularly for ten days after the sciatic nerve was cut and repaired, fibre growth rate rose 27% and conduction velocity 40% (Turchaninova et al., 2000); the effect persisted at delayed follow-up (Kolosova et al., 2002). No human outcome figure has been published (Anisimov et al., 2004).

Speculative 🟨

Protection of Brain Tissue Under Chronically Reduced Blood Flow

In rats with chronically reduced brain blood flow, Cortagen sped recovery of behaviour and blunted lipid peroxidation (the chemical damage reactive oxygen inflicts on fats) (Zarubina & Shabanov, 2011; 2016). No human data exist.

Reduction of Oxidative Damage Markers

Injected into rats, Cortagen lowered lipid-peroxidation products and oxidative modification of proteins in serum and cerebral cortex, while measured antioxidant enzyme activity fell alongside (Kozina, 2007). These are unvalidated biomarkers, not outcomes.

Loosening of Age-Condensed Chromatin

In lymphocytes cultured from donors aged 75 to 88, Cortagen activated ribosomal genes and decondensed age-tightened chromatin (Khavinson et al., 2004; Lezhava et al., 2023). Human cells in a dish; no human outcome.

Tissue-Specific Support of Brain Cortex Tissue Growth

In tissue culture, Cortagen stimulated growth of rat brain-cortex tissue specifically, not liver or thymus tissue (Khavinson, 2001; Khavinson et al., 2002). This is the entire basis of the tissue-specificity claim.

Shift in Cardiac Gene Expression

Five days of Cortagen altered 110 identified genes in the hearts of six-month-old female mice, overlapping partly with other bioregulator peptides and with melatonin (Anisimov et al., 2004). Direction of benefit was not established.

Immune Signalling Modulation ⚠️ Conflicted

Cortagen raised interleukin-2 (an immune signalling protein) gene activity in spleen cells (Kazakova et al., 2002) but did nothing in birds (Kuznik et al., 2008). Net reading: no reliable immune effect.

Benefit-Modifying Factors

  • Peptide transporter genotype: Uptake is attributed to proton-coupled oligopeptide transporters encoded by SLC15A1 and SLC15A2 (genes whose products ferry short peptide fragments across membranes). Common variants alter transport capacity for other substrates and could plausibly alter response, though no pharmacogenetic study of Cortagen exists.

  • APOE4 carriage: APOE4 (a variant of the gene for a cholesterol-carrying brain protein that raises Alzheimer’s risk) defines the group most drawn to neuroprotective peptides. No Cortagen study has stratified by it, so any expected benefit in carriers is unevidenced.

  • Baseline oxidative and inflammatory status: Rodent benefit appeared in animals with existing damage, reduced brain blood flow or a severed nerve, not in healthy controls. A person with low baseline inflammatory markers and intact nerve function has the least headroom for any effect.

  • Sex: Rodent nerve work used male rats; the cardiac gene-expression study used only female mice. No study has compared sexes, so nothing is known about whether response differs, and any assumption of equivalence is unsupported.

  • Pre-existing neurological injury: Every positive animal result required prior damage, either a severed nerve or reduced brain blood flow. Benefit in an uninjured, cognitively intact adult, the typical member of this audience, has never been tested in any species.

  • Age: The only human-cell work used donors aged 75 to 88, where chromatin condensation is already advanced. Whether a 45-year-old’s cells have enough age-related condensation for the same shift to occur has not been examined.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been documented for Cortagen in even one controlled human trial, let alone the two or more that this level requires, and no post-marketing safety surveillance system covers it.

Medium 🟥 🟥

No risk reaches Medium either: there is no single controlled human trial and no consistent observational dataset recording harm with Cortagen; the entire human record is uncontrolled clinical report from the originating programme.

Low 🟥

Contaminated or Misrepresented Product from Unregulated Supply

The one Cortagen hazard with human-market data, and a property of the supply chain rather than the molecule. With no approved product outside Russia, every vial comes from a research-chemical vendor with no oversight of identity, purity, sterility or endotoxin (fever-inducing bacterial fragments). Evidence is indirect; the channel is identical.

Magnitude: In a 2024 market-surveillance study of injectable peptide vials purchased online without prescription, measured purity was 7.7% to 14.4% against a 99% label claim, active content exceeded the stated amount by 28.6% to 38.7%, and endotoxin was present in every sample at 2.16 to 8.95 endotoxin units per milligram (Ashraf et al., 2024).

Speculative 🟨

Injection-Site Reaction, Abscess and Bloodstream Infection

Self-injection of a self-reconstituted powder carries the standard hazards of pain, bruising, sterile abscess and introduced infection. No Cortagen case series exists; the concern is generic to unregulated injectable peptide use (Coutinho et al., 2026).

Off-Target Gene Expression in Non-Target Tissue

Five days of dosing shifted 110 genes in mouse heart, an organ Cortagen is not aimed at, with changes up to 5.4-fold (Anisimov et al., 2004). Whether comparable shifts occur in humans is untested.

Theoretical Proliferative Risk from Chromatin Activation

The action claimed as a benefit, decondensing aged chromatin and switching ribosomal genes back on, is the reverse of the silencing that restrains damaged cells (Khavinson et al., 2004). No cancer-risk study of Cortagen exists.

Unpredictable Immune Effects ⚠️ Conflicted

Cortagen raised interleukin-2 gene activity in spleen cells (Kazakova et al., 2002) but shifted immune-cell output in opposite directions by age (Gumen et al., 2006). Net reading: direction is unpredictable, magnitude probably small.

Absence of Reproductive and Developmental Data

No reproductive toxicology, birth-defect study or breastfeeding data exists for Cortagen in any species. Effects on a pregnancy or a nursing infant are therefore wholly unknown rather than known to be absent.

Risk-Modifying Factors

  • Peptide transporter genotype: Variants in SLC15A1 and SLC15A2, the genes for the transporters that move short peptides into cells, would alter internal exposure for a given injected dose. Untested for Cortagen, so dose response cannot be individualised.

  • Baseline inflammatory markers: A person with an already elevated C-reactive protein (a blood marker of inflammation) cannot distinguish an endotoxin reaction to a contaminated vial from their underlying state, which removes the most useful early warning signal.

  • Sex: No sex-stratified safety data exist. Women are absent from the rodent nerve work entirely; the sole all-female study measured gene expression, not harm, so neither sex has a safety dataset to reason from.

  • Pre-existing immune and autoimmune conditions: Given rodent evidence of interleukin-2 and immune-cell modulation, anyone with active autoimmune disease or on immunosuppression faces an unquantified risk of altering that balance in an unpredictable direction.

  • Age: Immune-cell responses to short peptides ran in opposite directions in young and old mice. Older adults, the group most likely to use Cortagen, are therefore the group whose immune response is least predictable from the available data.

  • Reduced kidney or liver function: Peptide fragments and injection vehicle are cleared by the kidneys and liver. With no pharmacokinetic study in any population, impaired clearance means accumulation of unknown magnitude and unknown consequence.

Key Interactions & Contraindications

  • Immunosuppressants (monitor): With these immune-damping drugs (ciclosporin, tacrolimus, prednisolone), rodent-level interleukin-2 modulation could theoretically oppose intended suppression. Consequence would be transplant rejection or autoimmune flare. No human interaction study exists; the available mitigation is monitoring of drug levels and disease activity.

  • Peptide transporter substrates (caution): Oral drugs using the same peptide transporters, namely cephalosporin antibiotics (cefadroxil, cephalexin), valacyclovir and enalapril, could compete for uptake. Consequence is reduced effect of either agent; the usual mitigation is several hours’ separation between oral dosing and injection.

  • Other peptide bioregulators (caution): Stacking with Epitalon, Vilon, Pinealon or Cortexin is common and entirely untested. Consequence is not toxicity but unattributability: any benefit or adverse event cannot be assigned to a single agent. Single-compound introduction is the only mitigation.

  • Over-the-counter medications (caution): No interaction is documented with ibuprofen, paracetamol, oral antihistamines (allergy tablets) or stomach-acid reducers such as omeprazole. Injection bypasses the gut, so absorption-level interference is improbable; the practical consequence is that none has been looked for.

  • Anticoagulants and antiplatelet agents (caution): No chemical interaction is known. The residual risk with blood-thinning and clot-preventing drugs (warfarin, apixaban, clopidogrel) is mechanical: injection-site bruising or bleeding under the skin, mitigated by prolonged pressure after injection.

  • Antioxidant supplements (caution): N-acetylcysteine, alpha-lipoic acid and high-dose vitamin E act on the same lipid-peroxidation endpoint Cortagen lowered in rats, giving additive effects on that marker. Consequence is confounded interpretation rather than harm.

  • Other neuroprotective interventions (monitor): Cerebrolysin, citicoline and Semax target the same claimed endpoint of neuronal protection. Combined use produces overlapping and indistinguishable effects; consequence is an inflated impression of Cortagen’s contribution.

Populations who should avoid Cortagen:

  • Pregnancy and breastfeeding, at any stage, since no reproductive or developmental toxicology has ever been published
  • Active malignancy, or any blood cancer treated within the last 5 years, given untested effects on chromatin decondensation and ribosomal gene activation
  • Solid-organ transplant recipients on maintenance immunosuppression
  • Active autoimmune disease that has required escalation of therapy within the past 3 months
  • Severe kidney impairment, defined as estimated glomerular filtration rate below 30 mL/min/1.73 m²
  • Severe liver impairment, defined as Child-Pugh Class C, the most severe grade on the standard liver-function scoring system
  • Known hypersensitivity (allergic reaction) to any injected peptide or to bacteriostatic preservative
  • Anyone under 18 years of age

Risk Mitigation Strategies

  • Third-party certificate of analysis before first use: Independent high-performance liquid chromatography purity data and mass-spectrometry identity confirmation for the specific lot, not the vendor’s generic document. This addresses the documented 7.7% to 14.4% purity failures in unregulated peptide vials.

  • Lot-specific endotoxin and sterility testing: Limulus amoebocyte lysate results, the standard endotoxin assay, below 0.5 endotoxin units per milligram, plus sterility testing on the same lot. This targets the fever, chills and low-blood-pressure risk from contaminated injectate.

  • Single-agent introduction with a 4-week washout: Cortagen alone, with no other new peptide or supplement for at least 4 weeks either side. This makes any adverse event attributable and prevents the unattributability problem inherent in stacking.

  • Lowest published exposure first: Entry at the low end of any protocol, roughly 1 mg daily rather than 5 mg, for the first 3 days. This limits exposure to an uncharacterised compound before tolerability at the individual level is known.

  • Strict sterile injection technique: Alcohol swabbing of the vial septum and injection site, a fresh sterile needle per administration, site rotation, and disposal of reconstituted vials after 14 days refrigerated. This addresses abscess and bloodstream infection risk.

  • Pre-defined stopping rules: Immediate discontinuation for fever within 12 hours of injection, spreading injection-site redness beyond 5 cm, or any new neurological symptom. This converts an unmonitored experiment into one with a defined exit.

Therapeutic Protocol

  • Published animal course: Every positive rodent result used 10 µg/kg intramuscularly once daily for 10 consecutive days, begun immediately after injury (Turchaninova et al., 2000). No equivalent human course has been published in a trial.

  • Circulating human protocol: Vendor and practitioner protocols outside Russia specify 1 to 5 mg subcutaneously or intramuscularly once daily for 10 to 20 days, repeated two to four times yearly. These figures rest on convention, not published study.

  • Competing approach, the organ extract route: The alternative is the parent preparation Cortexin, an injectable cattle-brain polypeptide extract, or its oral cytamin equivalents. It carries actual registration and clinical use in Russia but an undefined composition.

  • Competing approach, the defined synthetic route: Cortagen offers a single known sequence and no animal-tissue contamination risk, at the cost of a far thinner clinical record. Neither route is the default; the trade-off is composition certainty against clinical familiarity.

  • Originators of each approach: Cortexin descends from Soviet military and neurological research and is manufactured commercially in Russia; Cortagen and the wider bioregulator programme come from Khavinson’s group at the St. Petersburg Institute, which patents and sells them.

  • Time of day: No study of dosing time exists for Cortagen. Protocols place the injection in the morning by convention only, reasoning that a compound proposed to affect gene activity is better given at a consistent daily point.

  • Half-life: Plasma half-life is minutes, as for any unprotected tetrapeptide exposed to circulating peptidases. The claimed effect therefore cannot depend on sustained blood levels, which is why courses are structured as pulses rather than continuous exposure.

  • Single versus split dosing: Every published protocol, animal and human, uses one daily administration. No study has compared split dosing, and the very short half-life means splitting would not meaningfully extend exposure.

  • Genetic polymorphisms: No pharmacogenetic data exist. The plausible modifiers are SLC15A1 and SLC15A2 transporter variants that govern short-peptide uptake, and, for anyone using it cognitively, APOE4 carriage. Neither has been tested with this compound.

  • Sex-based differences: Rodent efficacy work used males; the gene-expression study used females. No dose or response difference by sex has been examined, so protocols apply the same dose to both without evidence.

  • Age considerations: The only human-cell data come from donors aged 75 to 88. Older adults may have more age-condensed chromatin for the proposed mechanism to act on, but also less predictable immune responses to short peptides.

  • Baseline biomarkers: No biomarker predicts response. The pragmatic substitute is to record inflammatory markers, blood count and, where relevant, nerve conduction or cognitive scores before starting, so that any change has a reference point.

  • Pre-existing conditions: All positive animal work required existing nerve injury or reduced brain blood flow. Anyone with intact nerve function is applying an intervention outside every condition under which it has shown an effect.

Discontinuation & Cycling

  • Short-term by design: Cortagen is not a maintenance therapy. Every published protocol is a defined course of 10 to 20 days, on the premise that a shift in gene activity persists after the peptide is gone.

  • Withdrawal effects: None have been reported in animals or in the Russian clinical literature, and none would be expected pharmacologically, since a peptide cleared within minutes cannot produce physiological dependence or a rebound state.

  • Tapering: No taper is described or plausible. Courses stop abruptly at day 10 or day 20 in every protocol, and the very short half-life makes graded withdrawal meaningless.

  • Cycling: Cycling is intrinsic to the bioregulator model rather than a strategy for maintaining efficacy: courses are repeated two to four times yearly with months between. Whether repeat courses add anything has never been tested.

  • Persistence of effect: The one direct test found nerve-function benefit still present well after dosing ended (Kolosova et al., 2002), which is the sole empirical support for the pulsed-course structure.

Sourcing and Quality

  • No pharmaceutical-grade source outside Russia: There is no approved Cortagen product in the United States, the United Kingdom or the European Union. Every available vial is research-grade material sold under a not-for-human-use label, with no regulatory authority verifying its contents.

  • Purity documentation that matters: The relevant documents are lot-specific high-performance liquid chromatography purity above 98% and mass-spectrometry confirmation of the Ala-Glu-Asp-Pro mass. A vendor supplying only a generic or undated document is supplying no evidence at all.

  • Sterility and endotoxin data: Lyophilised, meaning freeze-dried, peptide can be sterile yet heavily contaminated with endotoxin, as market analysis of comparable vials has shown (Ashraf et al., 2024). Only a lot-specific Limulus amoebocyte lysate result, not a manufacturing claim, is evidence.

  • Formulation: Cortagen is supplied as a freeze-dried powder, typically 20 mg per vial, requiring reconstitution with bacteriostatic water. Oral cytamin-style preparations of brain peptide complexes exist but are compositionally different products, not oral Cortagen.

  • Compounding pharmacies: No reputable compounding pharmacy in a regulated market will prepare Cortagen, as it lacks an approved indication and an official pharmacy standard. Its absence from that channel is itself informative about the compound’s regulatory standing.

  • Storage and handling: Freeze-dried vials hold at minus 20 °C protected from light; after reconstitution the material keeps at 2 to 8 °C for 14 days. Peptide degradation is the quiet failure mode no certificate captures.

Practical Considerations

  • Time to effect: No human time course has been published. Animal nerve-regeneration effects were measured over the 10-day course and at delayed follow-up weeks later, so any expectation of a same-week subjective change is unsupported by the data.

  • Common pitfalls: The dominant errors are stacking several bioregulators at once, which makes attribution impossible; accepting vendor purity claims without lot-specific documentation; and extrapolating from the mouse cardiac gene-expression data as though it were a demonstrated human benefit.

  • Regulatory status: Cortagen has no approval from the U.S. Food and Drug Administration or the European Medicines Agency, and no recognised off-label pathway. It circulates as a research chemical; possession and personal import sit in an unsettled legal position in most jurisdictions.

  • Cost and accessibility: A 20 mg vial typically costs a modest amount relative to prescription peptides, so cost is not the limiting factor. Accessibility is limited instead by supply-chain quality and by the absence of any clinician willing to supervise its use.

  • Structural payer incentives: No insurer or national health system reimburses Cortagen anywhere, and none reimburses a competing brain-peptide product in Western markets, so no institutional payer has a financial stake in how this evidence is read.

Interaction with Foundational Habits

  • Sleep: No documented interaction. Cortagen is not sedating or stimulating, has no reported effect on sleep architecture, and its parent extract carries no sleep warning. Morning administration by convention avoids attributing sleep disturbance to injection timing, and sleep quality is worth logging as one of the few subjective markers for tracking response.

  • Nutrition: Indirect and mechanistically plausible. Uptake is proposed to occur through proton-coupled oligopeptide transporters that also carry di- and tripeptides released by protein digestion, so a large protein-rich meal could compete for those carriers. Injection largely bypasses the issue. No nutrient depletion has been reported, and no dietary pattern has been tested alongside Cortagen.

  • Exercise: No interaction is documented, and nothing suggests blunting of training adaptation, since the compound has no reported effect on muscle protein synthesis or on inflammatory signalling relevant to muscle growth. Rodent work paired it with recovery from injury, not with training. Where nerve recovery is the goal, structured rehabilitation has the controlled human evidence.

  • Stress management: Indirect at most. The peptide has no measured effect on cortisol or on the stress-hormone axis in any published study. Its rodent benefits appeared under physiological stress, so any effect would be on tissue consequences of stress rather than on the stress response itself. Established stress-reduction practice is not substitutable by it.

Monitoring Protocol & Defining Success

Because no validated response marker exists, monitoring here serves two purposes: detecting harm from an uncharacterised injected compound, and giving any claimed benefit a reference point it can be measured against. The baseline taken before the first injection covers an inflammatory marker, a full blood count, liver and kidney function, and whichever functional measure matches the reason for use, nerve conduction or a validated cognitive score. The safety panel is then repeated at the end of the first course, roughly day 10 to 20, at 3 months, and every 6 to 12 months where courses are repeated. Functional measures repeat only at 3 and 6 months, since neither nerve conduction nor cognitive scores move meaningfully over shorter intervals.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
High-sensitivity C-reactive protein Below 1.0 mg/L Detects a systemic inflammatory or endotoxin reaction to injected material C-reactive protein is a general blood marker of inflammation; the conventional laboratory cut-off is below 3.0 mg/L. Drawn fasting and at least 2 weeks clear of any infection
Complete blood count with differential Neutrophils 1.8–5.5 ×10⁹/L; lymphocytes 1.5–3.0 ×10⁹/L Cheapest way to catch the immune shift that rodent data make plausible Pair with the inflammatory marker on the same draw. A rising neutrophil count with fever after injection points to contamination rather than to the peptide
Alanine aminotransferase and aspartate aminotransferase ALT 10–26 U/L in men, 8–22 U/L in women; AST 10–26 U/L Baseline liver function before an uncharacterised compound with no toxicology ALT is alanine aminotransferase and AST aspartate aminotransferase, both liver enzymes released when liver cells are stressed. Conventional upper limits run to 40 U/L, well above the functional target
Estimated glomerular filtration rate Above 90 mL/min/1.73 m² Peptide fragments and injection vehicle are cleared by the kidneys eGFR is the estimated glomerular filtration rate, a calculated measure of kidney filtering capacity. Conventional concern begins below 60; strenuous exercise and creatine supplementation in the 48 hours before the draw distort the result
Nerve conduction velocity, affected nerve No established target for Cortagen; track change from the individual’s own baseline instead The only endpoint with any human precedent for this compound Requires a neurophysiology laboratory and the same operator and limb temperature each time. Relevant only where an existing nerve injury is the reason for use
Montreal Cognitive Assessment score 26–30 of 30 Gives the cognitive claim a measurable reference point rather than an impression The Montreal Cognitive Assessment is a validated 30-point screening test of memory, attention and executive function. Alternate test versions limit practice effects

Qualitative markers are worth logging in parallel, since they change before anything on the panel does:

  • Subjective mental clarity and word-finding ease, rated daily on a simple 1 to 10 scale
  • Sleep quality and time to fall asleep
  • Energy through the afternoon, when decline is most noticeable
  • For nerve injury, the return of sensation and any change in pins-and-needles or numbness
  • Injection-site appearance and any systemic symptom within 12 hours of dosing

Emerging Research

  • No registered trial of Cortagen anywhere: A ClinicalTrials.gov search on 31 August 2026 returned no interventional or observational study of Cortagen, and none of Epitalon, Cortexin or Semax either. The entire Khavinson bioregulator programme sits outside the international trial registry.

  • Class-adjacent trial that could move the field: CARE-EVT, NCT06339411 tests Cerebrolysin, a different pig-brain-derived peptide preparation and not Cortagen, after surgical clot removal for stroke. Phase 2, 100 participants, primary endpoint the final size of the brain injury on imaging, completing 2029.

  • Newest human-cell platform leaves AEDP untested: Kraskovskaya et al., 2024 aged human neurons from elderly donors and tested three sibling peptides (EDR, KED and AEDG) on the growth of dendrites, the branches of a nerve cell, and on oxidative DNA damage. Cortagen’s AEDP sequence was not among them.

  • Epigenetic mechanism awaits outside structural work: Khavinson et al., 2021 proposes sequence-specific DNA and histone binding. Independent structural biology from a laboratory with no commercial stake would either ground that mechanism or dissolve it, and would settle more than any further rodent study.

  • What would strengthen the case: A blinded, independently conducted replication of the rodent nerve-regeneration result, reproducing the reported growth-rate and conduction-velocity gains, would convert Cortagen’s founding claim from a single-programme finding into a reproducible one.

  • What would weaken it: A failed independent replication of that rodent result, a negative outcome in CARE-EVT, NCT06339411 for the wider brain-peptide neuroprotection premise, or a pharmacokinetic study showing the peptide never reaches brain tissue intact.

  • Safety data as the largest gap: No toxicology, gene-damage, cancer-risk or reproductive study exists for Cortagen in any species. Until one is published, the risk profile in this review rests on mechanism and on supply-chain analysis rather than on measurement.

Conclusion

Cortagen is a laboratory-made peptide of four amino acids, copied from the active part of an older brain-tissue extract and proposed to work by entering the cell nucleus and changing which genes a cell reads. Its founding claim, faster recovery after a nerve is severed, has one specific, so far uncontradicted rat result behind it, and a human claim that was asserted rather than shown. Everything else, brain protection under poor blood flow, less oxidative damage, looser packing of aged DNA, shifted heart gene activity, rests on animal work or on cells in a dish, and the compound did nothing in several experiments where closely related peptides were active.

The safety picture is neither reassuring nor alarming; it is empty. No animal safety testing, no pregnancy data, no measurement of how the body handles it in people, and no system collecting reports of harm. The one hazard with real numbers behind it belongs to the supply chain rather than the molecule: vials bought through unregulated channels have been found far below their stated purity and contaminated with fever-inducing bacterial fragments.

For an audience willing to weigh preliminary evidence, the honest reading is that this is an unusually clean idea attached to an unusually thin and financially interested body of work. Almost all of it comes from the institute that developed, patented and sells these peptides. That does not make the findings wrong. It does mean nothing here has yet been checked by anyone without a stake in the answer.

Top - Benefits - Risks - Protocol